fda ban on compounded semaglutide 🚨 Moves to Permanently Shut Down GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like and tirzepatide, signaling a major shift in how these semaglutide compounding fda news alerts

02.20.25 New analysis of NAION in diabetic patients An analysis of 37.1 million adults with type 2 diabetes across 14 databases found further evidence of an association between semaglutide and NAION. 01.30.25 Study found three eye diseases among semaglutide patients A small study focused on nine participants taking semaglutide and tirzepatide, a similar drug

Initial Consultation: Well discuss your symptoms, medical history, and any relevant test results to determine if B12 injections are right for you

They are related but different copper peptides

Dettweiler U, Simon P

The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)

Lipoic Acid hot ng nh mt cht chng oxy ha, gip bo v t bo khi tn thng do gc t do, h tr ti to cc cht chng oxy ha khc nh vitamin C v Glutathione, h tr lm chm qu trnh lo ha